What disease does trametinib treat?

Trametinib is an oral anticancer drug used to treat certain types of cancer, including advanced melanoma (skin cancer) and non-small cell lung cancer.

1.Advanced melanoma: Trametinib is approved to treat advanced or metastatic melanoma, also known as malignant melanoma. Melanoma is one of the most aggressive types of skin cancer. If not treated promptly, it can spread to other sites, seriously affecting patients' survival rates and quality of life. Trametinib is mainly suitable for patients with advanced melanoma who carry BRAF V600E or V600K mutations. These mutations are relatively common in melanoma and affect the normal function of cell signaling pathways. As a targeted therapy drug, trametinib interferes with abnormal signaling pathways by inhibiting the activity of MEK protein kinase, thereby inhibiting the proliferation and survival of melanoma cells and prolonging the survival of patients.

2.Non-small cell lung cancer: Trametinib is also used to treat BRAF V600Emutated non-small cell lung cancer (NSCLC). Although the BRAF V600E mutation is relatively rare in NSCLC, it is an important molecular subtype of NSCLC. These mutations lead to abnormal activity in cell signaling pathways, thereby promoting tumor growth and spread. Trametinib works by inhibiting the activity of MEK protein kinase and blocking this abnormal activity, thus inhibiting the proliferation and survival of NSCLC cells and providing an effective targeted treatment option for patients.

In summary, trametinib is an important targeted therapy drug, mainly used to treat patients with advanced melanoma with BRAF V600E or V600K mutations and non-small cell lung cancer patients with BRAF V600E mutations. Its targeting can slow or stop tumor growth, extend patient survival, and in some cases lead to tumor remission.